We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Molecular Test Detects More Cervical Cancer Cases

By LabMedica International staff writers
Posted on 06 Jun 2024
Print article
Image: Microscopic view of the HPV human papillomavirus that causes cervical cancer (credit: Adobe Stock Images)
Image: Microscopic view of the HPV human papillomavirus that causes cervical cancer (credit: Adobe Stock Images)

Cervical cancer screening is crucial for early detection and prevention. Many countries have comprehensive screening programs that begin with testing for various types of human papillomavirus (HPV), the virus responsible for cervical cancer. The traditional screening process involves a vaginal examination called a colposcopy if cell changes are detected. During a colposcopy, the gynecologist examines the cervix with a microscope and may take a biopsy if necessary. The biopsy, a surgical procedure, can result in negative pregnancy outcomes such as premature delivery. When an HPV-positive result is obtained, it is followed by cytological analysis, which involves examining gynecological cell samples under a microscope, relying on human interpretation. Researchers have now developed a simpler and more effective screening method for cervical cancer than the current one.

The WID-qCIN test, a new molecular test developed by researchers at Karolinska Institutet (Stockholm, Sweden) and the University of Innsbruck (Innsbruck, Austria), has the potential to replace cytological analysis. This test can automatically analyze epigenetic changes in cells, which are changes that influence which genes are active and which are not. Such changes can be affected by factors like the environment, lifestyle, and aging, and can raise the risk of cancer and other diseases. In a study involving more than 28,000 women over 30 who were screened in Stockholm between January and March 2017, the researchers used the WID-qCIN test along with a test for two high-risk HPV types (HPV 16 and 18) to analyze 2,377 HPV-positive samples. This method successfully detected 100% of all invasive cervical cancers and 93% of all serious precancerous lesions within a year of sampling.

Moreover, the new test, combined with the HPV 16/18 test, predicted 69% of all cancers and precancerous lesions up to six years after the sample was taken. In comparison, the current screening method predicts only 18%. In today's screening program, when cell changes are detected, a woman undergoes a vaginal examination (colposcopy), during which the gynecologist uses a microscope to look at the cervix and may take a biopsy if needed. This biopsy can lead to negative pregnancy outcomes, including premature delivery. The results of the recent study indicate that implementing the WID-qCIN test could reduce the number of colposcopy examinations by 40%. The study was published in Nature Medicine on June 4, 2024.

“By integrating the WID-qCIN test into our screening programs, we would be able to identify more cancer cases while reducing the need for invasive procedures,” said Joakim Dillner, Professor at Karolinska Institutet.

“With its simplicity and objective assessment, the WID-qCIN test can improve the effectiveness of these programs and support the global strategy to eliminate cervical cancer,” added Martin Widschwendter, Professor at the University of Innsbruck.

Related Links:
Karolinska Institutet
University of Innsbruck

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.